Analysis Tools
endocrine/exocrine glands
|
• insulin content is increased in the pancreas of tamoxifen treated mice
|
|
• total insulin content is higher in islets of tamoxifen treated mice than in controls
• islet cells from tamoxifen treated mice exhibit denser insulin granules in the beta-cells
• however, pancreatic islets exhibit normal morphology
|
|
• beta cells from tamoxifen treated mice exhibit an increased accumulation of insulin
|
|
• tamoxifen treated mice exhibit defective beta-cell function
|
|
• tamoxifen treated mice exhibit delayed glucose-stimulated insulin release
• islets from tamoxifen treated mice fail to show a timely increase in insulin secretion in response to glucose challenge or potassium chloride treatment
• however, tamoxifen treated mice exhibit normal insulin sensitivity and do not exhibit peripheral insulin resistance
|
homeostasis/metabolism
|
• tamoxifen treated mice exhibit delayed glucose-stimulated insulin release
• islets from tamoxifen treated mice fail to show a timely increase in insulin secretion in response to glucose challenge or potassium chloride treatment
• however, tamoxifen treated mice exhibit normal insulin sensitivity and do not exhibit peripheral insulin resistance
|
|
• fasting plasma glucose levels are elevated in tamoxifen treated mice
|
|
• mice develop hyperglycemia by day 6 of tamoxifen treatment that reaches peak levels by day 10
|
|
• fasting blood insulin levels are reduced in tamoxifen treated mice
• however, nonfasting blood insulin levels are normal in tamoxifen treated mice
• tamoxifen treated mice exhibit delayed and lower circulating insulin levels in response to a glucose challenge
|
|
• blood glucose levels of tamoxifen treated mice are greatly increased during the intraperitoneal glucose tolerance test, indicating delayed blood glucose clearance
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| type 2 diabetes mellitus | DOID:9352 |
OMIM:125853 OMIM:601283 OMIM:601407 OMIM:603694 OMIM:608036 |
J:225256 | |
N